First-in-Man Early Feasibility Study for Transcatheter HOCM Septal Ablation

Inclusion Criteria: * Males and females aged 20 years or older * NYHA(New York Heart Association) Class Ⅱ to Ⅳ in spite of optimal medical treatment. (For optimal medical treatment, β-blocker or diuretic such as calcium antagonists should be given for at least 3 months.) * Patients with left ventricular effusion gradient (LVOT) greater than (1) 30 mmHg at rest or (2) at least 50 mmHg at physiological exercise/dobutamine administration/balsalva manuver. (The pressure difference due to the left ventricle drain must be the proximal mitral valve-septal contact by the systolic motion of mitral valve (SAM).) * Patients who voluntarily decide to participate in this clinical trial and provide written informed consent. * Patients who are able to understand and follow instructions and participate for the entire duration of the clinical trial. Exclusion Criteria: * Target area wall thickness ≤15mm * LV ejection fraction ≤40% * Subjects who have unsuitable septal vein and coronary sinus anatomy by cardiac CT or venogram * Conduction disturbance; LBBB or RBBB * Advanced AV block without permanent pacemaker * Subjects who have experience in performing vascular stent procedures (PCI) or CABG on coronary arteries close to the coronary sinus within 3 months. * Severe pulmonary HTN ≥70mmHg * Patients who have cardiogenic shock and those who have an expected life expectancy of 12 months or less. * Patients with other valve diseases (companion disease) that require surgical treatment (in this case, Systolic motion of the mitral valve (SAM) caused by systolic myocardia is not considered a companion disease). * Patients who are pregnant, or lactating, or plan pregnacy during the clinical trials * Patients who are participated in other clinical trials within 1 month of enrollment * Patients who are deemed not to be eligible in this study by physician's discretion